(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced the appointment of Mr. Sylwester Cacek to the board of directors. Mr. Cacek’s appointment was effective March 7, 2014.
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the seventh dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion […]
(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening for the sixth dose level cohort in its ongoing Phase I/II clinical safety, tolerability and preliminary efficacy study of L-DOS47 in Poland. This follows completion […]
Helix BioPharma Corp. (TSX , FSE : ” HBP” ), a biopharmaceutical company dedicated to developing drugs for prevention and treatment of cancer, today announced that it has been advised by Dr. Marek Orlowski, a member of the board of directors of Helix and Chairman of the Supervisory Board of Helix Polska, that he has […]
AURORA, ONTARIO–(Marketwired – Dec 18, 2013) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix”), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, announces that its Annual General and Special Meeting (the “Meeting”) was held today as scheduled.
AURORA, ON–(Marketwired – Dec 17, 2013) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced that Mario Gobbo has resigned from Helix’s board of directors.
AURORA, ON–(Marketwired – Dec 13, 2013) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced financial results for the three-month period ended October 31, 2013.
AURORA, ON–(Marketwired – Dec 6, 2013) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has terminated its employment of John Docherty, effective immediately.
Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has completed a private placement with net proceeds in excess of CDN$4.6 million, after fees and expenses associated with this transaction.